Two Sigma Investments LP bought a new stake in Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 437,500 shares of the company's stock, valued at approximately $4,358,000. Two Sigma Investments LP owned 1.95% of Oaktree Acquisition Corp. III Life Sciences at the end of the most recent quarter.
Other institutional investors have also modified their holdings of the company. K2 Principal Fund L.P. purchased a new stake in shares of Oaktree Acquisition Corp. III Life Sciences in the fourth quarter valued at approximately $1,945,000. Sculptor Capital LP purchased a new stake in shares of Oaktree Acquisition Corp. III Life Sciences in the fourth quarter valued at approximately $2,490,000. TENOR CAPITAL MANAGEMENT Co. L.P. purchased a new stake in shares of Oaktree Acquisition Corp. III Life Sciences in the fourth quarter valued at approximately $2,988,000. Lighthouse Investment Partners LLC purchased a new stake in shares of Oaktree Acquisition Corp. III Life Sciences in the fourth quarter valued at approximately $3,039,000. Finally, Shaolin Capital Management LLC purchased a new stake in shares of Oaktree Acquisition Corp. III Life Sciences in the fourth quarter valued at approximately $5,478,000.
Oaktree Acquisition Corp. III Life Sciences Price Performance
Shares of Oaktree Acquisition Corp. III Life Sciences stock traded up $0.03 during trading on Monday, reaching $10.48. The company's stock had a trading volume of 87,116 shares, compared to its average volume of 115,396. Oaktree Acquisition Corp. III Life Sciences has a 12-month low of $9.95 and a 12-month high of $10.85. The business's 50 day simple moving average is $10.30.
Oaktree Acquisition Corp. III Life Sciences Profile
(
Free Report)
Oaktree Acquisition Corp. III Life Sciences is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 1995 and is headquartered in Los Angeles, CA.
See Also
Before you consider Oaktree Acquisition Corp. III Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oaktree Acquisition Corp. III Life Sciences wasn't on the list.
While Oaktree Acquisition Corp. III Life Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
